$AGTC Announces Pricing of $10 Million Underwritten Public Offering

August 3, 2022

GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 16,666,667 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to 16,666,667 shares of common stock at a combined public offering price of $0 …

Read the source article at Send Press Releases with GlobeNewswire
2022-07-13 02:01:43

Share This Story!